These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 18069281)

  • 1. [Molecular targeting therapy for multiple myeloma].
    Takatoku M
    Nihon Rinsho; 2007 Dec; 65(12):2345-50. PubMed ID: 18069281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and the current trends in multiple myeloma therapy.
    Dmoszyńska A
    Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in multiple myeloma.
    Chng WJ; Lau LG; Yusof N; Mow BM
    Cancer Control; 2005 Apr; 12(2):91-104. PubMed ID: 15855892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding novel therapeutic agents for multiple myeloma.
    Tariman JD
    Clin J Oncol Nurs; 2003; 7(5):521-8. PubMed ID: 14603548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical update: novel targets in multiple myeloma.
    Anderson KC
    Semin Oncol; 2004 Dec; 31(6 Suppl 16):27-32; discussion 33. PubMed ID: 15799242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma.
    Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
    Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The plasma cell myeloma--molecular pathogenesis and target therapies].
    Hess U
    Ther Umsch; 2006 Apr; 63(4):233-6. PubMed ID: 16689452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of drug therapy for multiple myeloma.
    Saunders G
    J Oncol Pharm Pract; 2005 Sep; 11(3):83-100. PubMed ID: 16390597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
    Lacy MQ; Tefferi A
    Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs in multiple myeloma.
    Berenson JR; Yellin O
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of double-refractory multiple myeloma.
    Meadows JP; Mark TM
    Curr Hematol Malig Rep; 2013 Dec; 8(4):253-60. PubMed ID: 23975677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatments for myeloma.
    Azaïs I; Brault R; Debiais F
    Joint Bone Spine; 2010 Jan; 77(1):20-6. PubMed ID: 20031467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide for bortezomib-resistant multiple myeloma.
    Briani C; Berno T; Campagnolo M; Zambello R
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824906
    [No Abstract]   [Full Text] [Related]  

  • 17. Lenalidomide efficacy in bortezomib-resistant myeloma.
    Gozzetti A; Crupi R; Defina M; Bocchia M
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple myeloma: increasing our treatment options.
    Alsina M
    Cancer Control; 2003; 10(5):357-8. PubMed ID: 14581889
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel agents in the frontline management of multiple myeloma.
    Loong HH
    Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.